{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:56:12Z","timestamp":1761173772409,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T00:00:00Z","timestamp":1711843200000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.purol.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T08:16:50Z","timestamp":1678349810000},"page":"254-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00c9valuation de l\u2019efficacit\u00e9 et de la tol\u00e9rance de la thermo-chimioth\u00e9rapie intrav\u00e9sicale HIVEC pour les tumeurs de vessie non infiltrant la musculeuse de risque interm\u00e9diaire et de haut risque"],"prefix":"10.1016","volume":"33","author":[{"given":"A.","family":"Cimier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Thach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.purol.2023.02.007_bib0165","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.purol.2023.02.007_bib0170","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1166-7087(20)30751-X","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU\u00a0\u2013\u00a0actualisation 2020\u20132022\u00a0: tumeurs de la vessie","volume":"30","author":"Roupr\u00eat","year":"2020","journal-title":"Prog Urol"},{"issue":"1B","key":"10.1016\/j.purol.2023.02.007_bib0175","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.purol.2023.02.007_bib0180","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2023.02.007_bib0185","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2023.02.007_bib0190","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.revmed.2005.08.017","article-title":"Nouveaut\u00e9s th\u00e9rapeutiques dans la prise en charge des carcinoses p\u00e9riton\u00e9ales d\u2019origine digestive\u00a0: chirurgie de cytor\u00e9duction et chimioth\u00e9rapie intrap\u00e9riton\u00e9ale","volume":"27","author":"Glehen","year":"2006","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.purol.2023.02.007_bib0195","unstructured":"Lammers, et al.\u00a0\u2013\u00a02011\u00a0\u2013\u00a0The role of a combined regimen with intravesical c.pdf."},{"issue":"6","key":"10.1016\/j.purol.2023.02.007_bib0200","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2023.02.007_bib0210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"10.1016\/j.purol.2023.02.007_bib0215","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2023.02.007_bib0220","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: the CUETO Scoring Model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2023.02.007_bib0225","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2023.02.007_bib0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of Bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.purol.2023.02.007_bib0235","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MOU.0000000000000544","article-title":"What to do during Bacillus Calmette\u2013Gu\u00e9rin shortage? Valid strategies based on evidence","volume":"28","author":"Abufaraj","year":"2018","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.purol.2023.02.007_bib0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00686169","article-title":"Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer","volume":"32","author":"Guillaume Wientjes","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.purol.2023.02.007_bib0245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.purol.2023.02.007_bib0250","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/02656736.2013.775355","article-title":"The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment","volume":"29","author":"Inman","year":"2013","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"10.1016\/j.purol.2023.02.007_bib0255","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1118\/1.3679839","article-title":"Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma: utility treatment planning for thermochemotherapy treatment bladder carcinoma","volume":"39","author":"Yuan","year":"2012","journal-title":"Med Phys"},{"issue":"4","key":"10.1016\/j.purol.2023.02.007_bib0260","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study","volume":"173","author":"van der Heijden","year":"2005","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2023.02.007_bib0265","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2023.02.007_bib0270","unstructured":"EAU-Non-muscle-Invasive-Bladder-Cancer-2021.pdf."},{"issue":"1","key":"10.1016\/j.purol.2023.02.007_bib0275","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.1038\/srep12083","article-title":"Radiofrequency treatment alters cancer cell phenotype","volume":"5","author":"Ware","year":"2015","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.purol.2023.02.007_bib0280","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.purol.2016.09.057","article-title":"Instillations endov\u00e9sicales dans les tumeurs de vessie n\u2019infiltrant pas le muscle (TVNIM). Perspectives d\u2019utilisation de la thermochimioth\u00e9rapie","volume":"26","author":"Irani","year":"2016","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2023.02.007_bib0285","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","author":"Tan","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2023.02.007_bib0205","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.purol.2023.02.007_bib0290","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1080\/02656736.2021.2002435","article-title":"Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy","volume":"38","author":"Doisy","year":"2021","journal-title":"Int J Hyperthermia"},{"issue":"5","key":"10.1016\/j.purol.2023.02.007_bib0295","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2023.02.007_bib0300","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011935.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Urology Group, \u00e9diteur","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev [Internet]"},{"issue":"4","key":"10.1016\/j.purol.2023.02.007_bib0305","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1464-410x.1999.00951.x","article-title":"Perivesical fat necrosis after adjuvant intravesical chemotherapy: perivesical fat necrosis after intravesical chemotherapy","volume":"83","author":"Doherty","year":"2001","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.purol.2023.02.007_bib0310","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2023.02.007_bib0315","doi-asserted-by":"crossref","first-page":"e1150","DOI":"10.1016\/S1569-9056(17)30717-0","article-title":"Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I and HIVEC II: an interim analysis of 307 patients","volume":"16","author":"Tan","year":"2017","journal-title":"Eur Urol Suppl"},{"issue":"5","key":"10.1016\/j.purol.2023.02.007_bib0160","first-page":"482","article-title":"An\u00e1lisis del impacto presupuestario del tratamiento mediante quimiohipertermia neoadyuvante en el c\u00e1ncer vesical no m\u00fasculo invasivo","volume":"68","author":"Sousa","year":"2015","journal-title":"Archivos Espa\u00f1oles de Urolog\u00eda"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708723000623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708723000623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:36:55Z","timestamp":1761115015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708723000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1166708723000623"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2023.02.007","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9valuation de l\u2019efficacit\u00e9 et de la tol\u00e9rance de la thermo-chimioth\u00e9rapie intrav\u00e9sicale HIVEC pour les tumeurs de vessie non infiltrant la musculeuse de risque interm\u00e9diaire et de haut risque","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}